Distinguished Health Centers and Experts Lead Recurrent Pericarditis, Acute Myocarditis Clinical Trials 

Any clinical trial program relies heavily on its administrators, advisors, and designers.…

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated…

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Toronto, Ontario–(Newsfile Corp. – November 16, 2023) – Cardiol Therapeutics Inc. (NASDAQ: CRDL)…

Clinical Trial for Recurrent Pericarditis Points to Cardiol Therapeutics’ Potential

When considering investment in a clinical-stage drug development company, it might be…